CORCEPT THERAPEUTICS INC

Corcept Therapeutics insider sales show routine portfolio moves, not a shift in strategy – a sign of long‑term confidence for investors.

Insightful insider selling at Corcept Therapeutics reveals strategic liquidity plans amid FDA review—key for investors to assess short‑term moves and long‑term confidence.

Corcept CFO buys 40,000 shares at $19.26—value‑buy hinting confidence amid heavy insider sales, guiding investors on potential upside and risk.

Insider buying spree by Corcept Therapeutics’ CDO William Guyer shows confidence in the company’s cortisol‑modulating therapy and signals potential upside, but investors should watch market volatility and corporate moves.

Insider buying at Corcept Therapeutics signals confidence amid litigation; executives stack shares as cortisol‑therapy pipeline progresses.

Explore how Lyon Douglas’s 5,000‑share sale amid Corcept’s rally signals liquidity needs and insider confidence shifts—insightful for investors watching stock dynamics.

Corcept insider Guyer buys 20k shares at $21.65—deep‑discount to $52—while selling options, hinting confidence in cortisol‑drug pipeline and potential upside.

Corcept insider buys reveal executive confidence amid legal risk, showing disciplined buying and long‑term optimism for investors.

CEO Joseph Belanoff sells 26k Corcept shares via a pre‑planned 10b5‑1 plan, after FDA approval of Lifyorli, yet the move signals routine liquidity, not a sell‑off.

Corcept insider trading: Guyer William’s recent buy‑sell cycle signals confidence and strategic liquidity management, hinting at potential upside if the pipeline progresses.